# Andrew Cleeland

> Andrew Cleeland is an Australian-born medtech executive and operator who leads Fogarty Innovation in Mountain View, California. After beginning at Australia’s Therapeutic Goods Administration and working through large companies and Silicon Valley startups, he led Ardian and Twelve to acquisitions by Medtronic worth more than $1.7 billion combined. Since 2017, he has applied those lessons to Fogarty’s nonprofit model of incubation, education, alliances, and hands-on mentorship.

- **Role:** Chief Executive Officer at Fogarty Innovation
- **Organizations:** Fogarty Innovation, Ardian, Twelve, Medtronic, Radiant Medical, Baxter Healthcare, Telectronics, Australian Therapeutic Goods Administration, The Foundry, Longitude Capital, Arboretum Ventures, Saluda Medical, Zenflow, MMI
- **From:** Melbourne, Australia
- **Nationality:** Australian
- **Education:** Bachelor of Applied Science in Biophysics, Swinburne Institute of Technology
- **Known for:** Led Ardian through a Medtronic acquisition valued at more than $1.3 billion., Led Twelve through a Medtronic acquisition valued at up to $458 million., Expanded Fogarty Innovation’s work across incubation, education, and ecosystem alliances.

## Career timeline

- **Early career** — Began in medical-device regulation at Australia’s Therapeutic Goods Administration.
- **1990s** — Moved from Australia to Denver for a role at Telectronics, then joined Baxter Healthcare’s Novacor division.
- **Late 1990s** — Entered the Silicon Valley startup ecosystem as vice president of clinical and regulatory affairs at Radiant Medical.
- **2003-2011** — Served as president and CEO of Ardian; Medtronic acquired the company in a transaction valued above $1.3 billion.
- **2012-2015** — Served as president and CEO of Twelve; Medtronic acquired it for up to $458 million.
- **2015-2017** — Served as vice president and general manager of Medtronic’s transcatheter mitral valve program.
- **2017-present** — Leads Fogarty Innovation as CEO.
- **2025** — Helped lead Fogarty Innovation’s strategic merger with the Cardiovascular Research Foundation and launch the inaugural Thomas J. Fogarty Innovation Prize.

## Achievements

- Led Ardian through a Medtronic acquisition valued at more than $1.3 billion.
- Led Twelve through a Medtronic acquisition valued at up to $458 million.
- Expanded Fogarty Innovation’s work across incubation, education, and ecosystem alliances.
- Hosts Fogarty Innovation’s MedTech Trailblazers interview series.
- Helped establish Fogarty Innovation as the Cardiovascular Research Foundation’s West Coast Innovation Hub through their 2025 merger.
- Helped launch the Thomas J. Fogarty Innovation Prize, first awarded in 2025.

## Latest updates

- **2025-12** — Published a year-end reflection describing resilient hope and partnership as catalysts for progress in medtech innovation.
- **2025-11** — Explained Fogarty Innovation’s merger with the Cardiovascular Research Foundation and reflected on the inaugural Thomas J. Fogarty Innovation Prize.
- **2025-10** — Fogarty Innovation announced its strategic merger with the Cardiovascular Research Foundation and became its West Coast Innovation Hub.
- **2025-10** — The inaugural Thomas J. Fogarty Innovation Prize was awarded to the FARAPULSE team at a San Francisco gala.
- **2025-03** — Appeared on DeviceTalks Weekly to discuss his medtech career, startup leadership, and concerns about the industry.

## Links

- Website: https://www.fogartyinnovation.org
- LinkedIn: https://www.linkedin.com/in/andrew-cleeland-7024a44
- Twitter/X: https://twitter.com/FogartyInnov
- YouTube: https://www.youtube.com/channel/UCDwIkuOksDXkmnbUufRcZHw
- Instagram: https://www.instagram.com/fogartyinnovation/
- Facebook: https://www.facebook.com/fogartyinnovation

---

Profile page: https://yespress.io/andrew-cleeland
Published by YesPress — https://yespress.io
Last updated: 2026-08-17